Navigation Links
Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Date:5/6/2010

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at two investor conferences in the coming week.  David Loury PhD, Chief Scientific Officer, will be presenting at the MDB Bright Lights Conference in San Francisco, CA at the Palace Hotel on Tuesday, May 11 at 4:00 P.M. PDT.  Joseph Buggy PhD, Vice President of Research, will be presenting at the Bank of America Merrill Lynch Healthcare Conference in New York, NY at the Grand Hyatt on Wednesday, May 12 at 4:20 P.M. EDT/1:20 P.M. PDT.

There will be a live webcast of the Bank of America Merrill Lynch conference presentation, which will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our mission and goal are worth repeating: to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
2. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
3. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
4. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
5. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
6. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
7. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
8. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) today ... effective Aug. 7, 2017. ... interests and will serve as president emeritus during a planned, ... in multiple leadership roles since he joined Diplomat with the ... provided decisive, strategic leadership which continues to benefit our patients ...
Breaking Medicine Technology:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Room (ER) on Wednesday, August 16, to community partners. The newly renovated ER ... “Fast Track” area for minor emergencies, eight semi-private rooms to deliver patient results, ...
(Date:8/17/2017)... ... 17, 2017 , ... An August 2 article on NextShark discusses ... largely influenced by the growing popularity of “pretty boys” in both K-Pop and television ... of male appearance are changing not only in the Asian nation, where plastic surgery ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... care professionals, today announced that it has raised $1.675 M in seed funding ... Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s primary ...
(Date:8/17/2017)... ... August 17, 2017 , ... Momkus McCluskey Roberts LLC ... Parks is a member of the firm’s Commercial Litigation and Employment Law groups. , ... wealth of knowledge in matters of employment litigation, commercial litigation and business disputes. Her ...
(Date:8/17/2017)... ... 2017 , ... Finalists in the 2017 (second annual) ... awards recognize the world’s best employers and the human resources professionals, teams, achievements ... to work. , A diverse group of organizations and individuals around the world ...
Breaking Medicine News(10 mins):